Neonatal intensive care unit preparedness for the Novel Coronavirus Disease-2019 pandemic: A New York City hospital perspective

Verma, Sourabh; Lumba, Rishi; Lighter, Jennifer; Bailey, Sean M.; Wachtel, Elena V.; Kunjumon, Bgee; Alessi, Samantha; Mally, Pradeep

doi:10.1016/j.cppeds.2020.100795

Cited by 21 publications

(30 citation statements)

References 16 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is known that SARS-CoV-2 attaches to angiotensin converting enzyme-2 (ACE2) receptors to enter cells. Due to the widespread presence of ACE2 receptor on neurons, it is thought that neonates with COVID-19 may develop a pertussis-like respiratory center suppression [6]. Because of the nonspecific clinical presentation of COVID-19 in neonates, it is critical for clinicians to keep in mind the common causes of respiratory distress (Table 1) in this population [27].…”

Section: Making the Diagnosis Of Sars-cov-2 In Neonates Clinical Charmentioning

confidence: 99%

“…Neonates with COVID-19 should be managed by a multi-disciplinary team comprising of obstetricians, neonatologists, intensive care specialists, radiologists, specialists in infection prevention and control (IPC), and specialist nurses, who must be oriented in SARS-CoV-2 management and IPC strategies. Both clinicians and families should routinely receive psychological support by social workers and psychologists [6,8]. At this point, it is important to understand that as the pandemic is evolving, scientific evidence is changing rapidly.…”

Section: Managementmentioning

confidence: 99%

“…At this point, it is important to understand that as the pandemic is evolving, scientific evidence is changing rapidly. As such, clinicians need to be updated with current protocols [6].…”

Section: Managementmentioning

confidence: 99%

“…The SARS-Cov-2 virus is an enveloped positive-sense single-stranded RNA (+ssRNA) β-coronavirus with more than half of its genomic sequence identical to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). In 2002-2003 and 2012, SARS-CoV and MERS-CoV caused major epidemics in China and the Middle East respectively [6,7].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Untitled

2020

JPNB

View full text Add to dashboard Cite

Section: Making the Diagnosis Of Sars-cov-2 In Neonates Clinical Charmentioning

confidence: 99%

Section: Managementmentioning

confidence: 99%

“…At this point, it is important to understand that as the pandemic is evolving, scientific evidence is changing rapidly. As such, clinicians need to be updated with current protocols [6].…”

Section: Managementmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Untitled

2020

JPNB

View full text Add to dashboard Cite

“…Hopefully, several extreme measures will not be needed, especially if very rapid and reliable tests become available. For the time being, it seems reasonable to use the available published COVID-19 NICU protocols [13][14][15], and increase surveillance when case-rates rise locally; unfortunately probably a necessary condition we will continue to face for some time.…”

mentioning

confidence: 99%

COVID-19 surveillance for all newborns at the NICU; conditio sine qua non?

2020

View full text Add to dashboard Cite

Previous studies have reported fewer cases of Coronavirus disease 2019 (COVID-19) in children than in adults, and to date there is limited literature about the clinical course and outcomes in neonates [1, 2]. Not inappropriately the focus of COVID-19 therapies has been in adults, especially the aged. However, it is clear that an immature immune system makes neonates, especially those in the NICU, highly vulnerable to infections generally [3, 4], and thus probably also for COVID-19. One case series has suggested that the younger the child, the higher risk of severe COVID-19 disease [5]. The first report of a neonate with COVID-19 infection was a 17 days old boy who recovered [6]. At the time of writing, complete data 1 on 35 neonates have been included in the database EPICENTRE [7]. Vertical risk was present in 33 neonates, and only two infants were reported to have community exposure. As more neonates are included in well-designed databases, the more we understand the risks, clinical spectrum, severity and complications in this patient population. Moreover, we can focus on ways to prevent COVID-19 infections in neonates born from an infected mother, or neonates that are infected in the community, whether at home, in hospital, by health care workers or families, especially during any potential new pandemic waves.

show abstract

Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review

Al-Qudimat

Al‐Zoubi

Elaarag

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background & Aims: The BioNTech-Pfizer vaccine is the only vaccine offered to children among all available vaccines. However, limited evidence is available about the clinical outcomes of COVID-19 vaccines, especially among children and adolescents. This review offers a comprehensive and up-to-date overview of the BioNTech-Pfizer vaccine's current information on children and adolescents. Methods: The review was conducted following the PRISMA guidelines; a comprehensive search was performed in PubMed, Scopus, MEDLINE, and EMBASE databases for research publications COVID-19 published between December 2019 and October 2021. All studies reporting on the outcomes of vaccinating children in their respective institutes were included.Results: A total of 78 vaccinated children and adolescents from six studies were included. The majority of symptomatic vaccinated pediatrics were males (71%). The mean age was 15.6 years, and the BMI was 24.1. The most common clinical symptoms were found in chest pain (35%), fever (32%), and myalgia (17%). The most common cardiac symptom in the EKG results was ST elevation, and 35% of vaccinated pediatrics had elevated serum troponin. The hospitalization, including ICU admission, was lower than in unvaccinated groups. Statistically significant associations (p ≤ 0.05) were found in two symptoms (fever and headache) between the vaccinated and nonvaccinated pediatric groups.Conclusions: Although we found better outcomes in the vaccinated group versus the nonvaccinated pediatric group, more studies are still crucial to further understand the specific etiology underlying postvaccination, particularly myocarditis, psychological impact, and other cardiac clinical symptoms in children and adolescents after receiving the BioNTech-Pfizer vaccine.

show abstract

Neonatal intensive care unit preparedness for the Novel Coronavirus Disease-2019 pandemic: A New York City hospital perspective

Cited by 21 publications

References 16 publications

Untitled

Untitled

COVID-19 surveillance for all newborns at the NICU; conditio sine qua non?

Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review

Contact Info

Product

Resources

About